The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy–taxane (FACT‐taxane)
Abstract
BACKGROUND: Cancer chemotherapy with some of the taxane class of agents can be associated with significant neurotoxicity, arthralgias, myalgias, and skin changes that may offset the therapeutic benefits of taxane use. METHODS: The authors developed and tested a set of questions to assess these important side effects of taxane therapy from the patient's perspective. The current study evaluated the taxane subscale of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Reliability, validity, and responsiveness to expected change were evaluated in the context of an ongoing clinical trial comparing four cycles of carboplatin plus paclitaxel with a strategy of carboplatin plus paclitaxel until disease progression in patients with advanced nonsmall cell lung carcinoma (NSCLC). RESULTS: The 16‐item Taxane subscale score and the 11‐item peripheral neuropathy subset both demonstrated excellent internal consistency and concurrent validity, and the scores worsened as one would predict during a 12‐week treatment course of taxane therapy. Results of the psychometric analyses supported the use of this subscale for measuring the unwanted adverse consequences of effective cancer therapies. Measuring the patient perception of treatment side effects also allowed a preliminary exploration of the relative quality of life (QOL) impact of symptom relief and treatment toxicity. The results indicated that toxicity and symptom improvement may make relatively equivalent contributions to total QOL as measured by the summary score from a multidimensional QOL instrument, the Functional Assessment of Cancer Therapy–General. However, symptom status and improvement appear to play a stronger role than taxane toxicity in patients' global rating of their QOL. CONCLUSIONS: Future research might examine this question of competing benefits as a potential aid to decision‐making regarding the administration of toxic therapies in the setting of advanced disease. Cancer 2003;98:822–31. © 2003 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citationPromotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Quality of life and pharmacoeconomics in clinical trials
Pater, J. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)82191-5 · Cited by 2,395
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00071-2 · Cited by 862
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citationCELLA, D., ETON, D., FAIRCLOUGH, D., BONOMI, P., HEYES, A., SILBERMAN, C., WOLF, M., & JOHNSON, D. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00477-2 · Cited by 380
Self-citation
Cited by
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,083
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Self-citationChemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.012 · Cited by 583
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
Flatters, S. J. L., & Bennett, G. J. (2004) · Pain · doi:10.1016/j.pain.2004.01.029 · Cited by 576
Fleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Self-citationPeripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.010 · Cited by 408
Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2255-7 · Cited by 374
Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370
Self-citationPatient Online Self-Reporting of Toxicity Symptoms During Chemotherapy
Basch, E., Artz, D., Dulko, D., Scher, K., Sabbatini, P., Hensley, M., Mitra, N., Speakman, J., McCabe, M., & Schrag, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.275 · Cited by 310
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial
Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., Reid, R. D., Cook, D., Jespersen, D., Proulx, C., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt297 · Cited by 297
Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., & Bidoli, P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.008 · Cited by 274
Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
Pachman, D. R., Barton, D. L., Watson, J. C., & Loprinzi, C. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.115 · Cited by 268
Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., Awad, D., & Crew, K. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1278-0 · Cited by 264
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159
“Numerous patient-reported tools have been validated [75]; however, the Functional Assessment of Cancer Therapy (FACT)Taxane tool is the only taxane-specific tool for assessing patient-reported taxane-related symptoms, including neuropathy [76].”
MethodVictorson, D., Barocas, J., Song, J., & Cella, D. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9398-2 · Cited by 141
Self-citationShelby, R. A., Edmond, S. N., Wren, A. A., Keefe, F. J., Peppercorn, J. M., Marcom, P. K., Blackwell, K. L., & Kimmick, G. G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2269-1 · Cited by 76
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72
Metadata
- Authors
- Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-06-20
- Volume
- 98
- Issue
- 4
- Pages
- 822-831
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2033923474
- Cited by
- 286
- References
- 17
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.